These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23636010)

  • 1. Plasma renin and cardiovascular risk: what is the evidence for an association?
    Volpe M; Unger T
    Cardiology; 2013; 125(1):50-9. PubMed ID: 23636010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin and prorenin as biomarkers in hypertension.
    Jan Danser AH
    Curr Opin Nephrol Hypertens; 2012 Sep; 21(5):508-14. PubMed ID: 22820372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives.
    de la Sierra A
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1585-91. PubMed ID: 22103877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.
    Abdellatif AA
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):251-63. PubMed ID: 22292880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels.
    Sealey JE; Alderman MH; Furberg CD; Laragh JH
    Am J Hypertens; 2013 Jun; 26(6):727-38. PubMed ID: 23548411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
    Gullapalli N; Bloch MJ; Basile J
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin as a biomarker of cardiovascular disease in clinical practice.
    Volpe M; Battistoni A; Chin D; Rubattu S; Tocci G
    Nutr Metab Cardiovasc Dis; 2012 Apr; 22(4):312-7. PubMed ID: 22402063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.